Patients with acute low-risk pulmonary embolism (PE), which includes the absence of right ventricular dysfunction and intracardiac thrombi, can be discharged early and further treated at home with rivaroxaban. This strategy has shown to be effective, safe, as well as feasible in the Home Treatment of Pulmonary Embolism (HoT-PE) trial .
The HoT-PE trial was a prospective, international, multicentre, single-arm phase 4 trial with 3-month follow-up (plus 1-year follow-up for survival). Primary outcome was recurrent symptomatic venous thromboembolism (VTE), or death due to recurrent PE, within 3 months of enrolment. A total of 525 patients with objectively confirmed PE within 24 hours of presentation were enrolled. These patients received the first dose of rivaroxaban 15 mg twice daily in the hospital and continued for 3 weeks after discharge, followed by rivaroxaban once daily 20 mg, or 15 mg in select patients for at least 3 months. The mean age of patien...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Findings from 2 studies indicate sustained long-term quality of life: nivolumab with or without ipilimumab in previously untreated advanced melanoma Next Article
High 5-year survival rates for older HF patients without initial severe comorbidity »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.